ReviewNature cancer2025
The current and emerging immunotherapy paradigm in small-cell lung cancer.
Review in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07390565 (Yishen Qutong Granules Combined With Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Yishen Qutong Granules Combined With Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: A Multicentre, Randomised, Triple-Blind, Placebo-Controlled Trial
Who cites it
19 citing papers in PubMed.
- Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209).Frontiers in immunology · 2026Trial
- Curcumol Inhibits the Laminin-Facilitated Malignant Progression in Small-Cell Lung Cancer via Disrupting Laminin-Integrin β1 Interaction.Phytotherapy research : PTR · 2026Article
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- OX40 (TNFRSF4) Tracks Immune Infiltration in Small Cell Lung Cancer and Shows a Cohort-Specific, Non-Replicated Association with the POU2F3/SCLC-P Subtype: A Multi-Source In Silico Analysis.International journal of molecular sciences · 2026Article
- Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study.Translational lung cancer research · 2026Article
- Engineering T cell therapies for lung cancer.Molecular therapy. Oncology · 2026Article
- Acidic-responsive nano liposomes potentiate in situ dual immunotherapy on lung cancer by codelivering antagonistic peptide and agonist.International journal of pharmaceutics: X · 2026Article
- Surgery versus radiotherapy after neoadjuvant immunochemotherapy in limited-stage small cell lung cancer.Journal of thoracic disease · 2026Article
- Research progress on immune microenvironment and biomarkers of small cell lung cancer.Journal of thoracic disease · 2026Review
- Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.Current treatment options in oncology · 2026Review
- [Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- The Wnt receptor Frizzled3 (FZD3) drives aggressive phenotypes in small cell lung cancer.Respiratory research · 2026Article
- Serum ferritin change rate combined with a multidimensional inflammation model for predicting efficacy and survival in extensive-stage small-cell lung cancer patients undergoing immunotherapy: a single-center, retrospective cohort study.Frontiers in immunology · 2026Article
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
- Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Lung cancer immunotherapy in 2025: where we stand and what comes next?Frontiers in immunology · 2025Review
- Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer.Frontiers in immunology · 2025Article
- Adebrelimab Combined with Chemotherapy for Esophageal Neuroendocrine Carcinoma: A Case Report.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Small-cell lung cancer (SCLC) is a highly aggressive malignancy with poor prognosis. For decades, etoposide-platinum-based chemotherapy had been the mainstay treatment for SCLC; however, despite initial high response rates, most patients developed resistance. In 2019, the US Food and Drug Administration approved the anti-PD-L1 antibody atezolizumab in combination with etoposide-platinum as the new first-line standard of care for extensive-stage SCLC, heralding a paradigm shift in SCLC therapy. This Review aims to provide an overview of the current landscape and emerging treatment strategies of immunotherapies in SCLC as well as highlight the importance of developing biomarkers to facilitate patient selection.
Indexed as
Identifiers
40473974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.